The Ibogaine Story — Chapter 18: Deborah Mash's Brain
AI-extracted · unverified · confirm at source
Detailed insider account of 1994-95 NIDA ibogaine review, Panama treatments, Mash's noribogaine pharmacokinetics, three ibogaine-associated deaths, and political forces that blocked the Phase I/II trial.
Dosing: 8–31 mg/kg oral (range across Panama treatments); FDA approved Miami protocol at 8 mg/kg; Baumann used ~half recommended dose; Nancy received 25, 29–31, and split 10+20 mg/kg across three treatments (oral)
Contraindications: Pre-existing coronary artery disease (80% arterial sclerosis cited as contraindication violation in Baumann death), Concurrent opioid use at time of dosing (opiates in urine at time of Baumann treatment), CYP2D6 slow metaboliser status (prolonged noribogaine exposure implicated in Nicola K. death), Female sensitivity — lower dosing recommended (split dosing used for Nancy's third treatment)